Merck (MRK) Begins Global Phase 3 COPD Trial

• Merck (NYSE:MRK) began the global Phase 3 ENHANCE-3 COPD trial for OHTUVAYRE (ensifentrine), a first-in-class inhaled therapy.
• The drugmaker reported new oncology data, including fresh trial readouts for KEYTRUDA and antibody drug conjugate candidate sacituzumab tirumotecan.
• Merck outlined progress in HIV research with long-acting oral regimens and upcoming regulatory milestones for its pipeline candidates.
• The group agreed to sell its Life Science CDMO business to Lonza, refocusing resources on research driven segments. This mix of OHTUVAYRE trial expansion, oncology and HIV updates, and the CDMO sale only captures part of what matters for Merck today. We have also spotted 5 warning signs worth knowing about at Merck.

For a broader view on where drug development is intersecting with next generation tech, it is worth looking at 38 healthcare AI stocks.

Merck operates as a global healthcare group in the pharmaceuticals industry, so large late stage trials and portfolio reshaping moves like the CDMO sale speak directly to how it allocates its scale and R&D focus across respiratory disease, oncology and HIV treatments.

2 things going right for Merck that this headline doesn't cover.

How does the ENHANCE-3 COPD trial alter Merck’s respiratory story?

OHTUVAYRE is already cleared in the US for COPD maintenance, so ENHANCE-3 is less about first approval and more about showing whether it can cut moderate and severe exacerbations on top of standard inhalers. The trial’s 2,136 patient scale across 28 countries, with a 52 week primary endpoint, signals that Merck is testing OHTUVAYRE as a long haul, outcomes focused respiratory asset.

Does this news change the Merck Narrative investors have been tracking?

The current Narrative focuses on Merck turning late stage programs like sacituzumab tirumotecan, intismeran and new HIV regimens into sizeable franchises that help during and after the KEYTRUDA window. Recent Phase 3 wins in endometrial cancer, melanoma and the expanding HIV data set relate directly to that catalyst, although recent guidance and earnings suggest the share price already reflects confidence in this broad pipeline plan.

See how these catalysts shape Merck's path to a $160 fair value.

What should investors watch next to see if these moves really matter for Merck?

Focus on concrete decision points rather than headlines. Key markers include the FDA’s June 15, 2027 target action date for sacituzumab tirumotecan, the April 22, 2027 PDUFA dates for the IDVYNSO HIV submissions, recruitment progress and early readouts from ENHANCE-3, and any detail Merck provides on how proceeds from the Life Science CDMO sale will be redeployed into oncology, respiratory and HIV programs.

The extra Merck check many buyers run before pressing the button

Before acting on any headline, some investors zoom out and study where current analyst projections say Merck could be a few years from now, because those long range expectations often point in a direction today’s updates do not. See where analysts expect Merck to be in a few years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com